SNN Stock Analysis: Buy, Sell, or Hold?
SNN - Smith & Nephew plc
$29.54
-0.18 (-0.61%)
▼
5d:
-1.37%
30d:
-12.68%
90d:
-18.35%
HOLD
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Get Alerted When SNN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SNN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: SNN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$52.95
Based on 8.2% avg growth
INTRINSIC VALUE TODAY
$32.88
10.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SNN is currently trading at $29.54, which is considered oversold relative to its 30-day fair value range of $30.39 to $33.55. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.2) compared to its historical average (17.1). Remarkably, the market is currently pricing in an annual earnings decline of 6.0% over the next few years. This pessimistic expectation contrasts with the company's recent 70.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, SNN is in a downtrend. The price is currently testing key support at $29.08. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SNN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $34.99 (+17.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SNN is in a downtrend. The price is currently testing key support at $29.08. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SNN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $34.99 (+17.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$30.39 -
$33.55
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
54.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($34.99)
Trading Range Analysis
30-Day Trading Range
$30.39 -
$33.55
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$29.08
Resistance Level
$31.63
Current Trend
Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.21
Wall Street Target
$34.99
(+17.7%)
Revenue Growth (YoY)
7.4%
Earnings Growth (YoY)
70.4%
Profit Margin
10.1%
Valuation Discount vs History
-6.0% cheaper
PE vs Historical
14.2 vs 17.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.0%
(market-implied from PE analysis)
1-Year Target
$27.94
(-6%)
2-Year Target
$26.26
(-12%)
3-Year Target
$24.68
(-17%)
3-Yr Target (if PE normalizes)
(PE: 14→17)
$29.71
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 12.4%)
$65.45
(+120%)
Base:
(SPY PE: 14.2, Growth: 12.4%)
$42.19
(+42%)
Bear:
(PE: 12.1, Growth: 12.4%)
$35.86
(+21%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 20.84 | Current EPS (TTM): $1.43
Bull Case
$47.95
(+61%)
Analyst growth 46.3%, PE expands to 22.9
Base Case
$43.59
(+47%)
Market implied 46.3%, PE stable at 20.8
Bear Case
$20.26
(-32%)
Severe decline -20.0%, PE contracts to 17.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.2 to 17.1
Stabilization Target:
$35.77
(+20.4%)
PE Expansion Potential:
+20.4%
Share & Embed Analysis
Last updated: May 15, 2026 4:15 PM ET
Data refreshes hourly during market hours. Next update: 5:15 PM
Data refreshes hourly during market hours. Next update: 5:15 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$85 | 59 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$84 | 66 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$108 | 64 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$119 | 55 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 55 HOLD |
